Marlin Equity Partners has completed a majority growth investment in Radar Healthcare, aimed at enhancing its product development and supporting international expansion in the healthcare software market.

Information on the Target

Radar Healthcare, a leading provider of risk, quality, and compliance software, is dedicated to enhancing healthcare and social care services. The Company supports over 250 participants globally, focusing on patient safety and care excellence. Its comprehensive suite of solutions aims to foster improved care outcomes while addressing the challenges faced by healthcare providers.

By integrating digital innovation with healthcare expertise, Radar Healthcare creates systems that not only comply with regulatory standards but also enhance operational efficiency. The partnership with Marlin Equity Partners is anticipated to further strengthen Radar’s market presence and accelerate product development and international expansion.

Industry Overview

The healthcare and social care sectors have witnessed significant growth and transformation in recent years, driven by technological advancements and increasing demand for integrated care solutions. I

View Source

Similar Deals

Growth Lending A & R Care Limited

2025

Growth Equity & Expansion Capital Residential & Long-Term Care United Kingdom
Foresight Group Functional Gut Group

2025

Growth Equity & Expansion Capital Medical & Diagnostic Laboratories United Kingdom
NorthEdge RoukenBio

2024

Growth Equity & Expansion Capital Biotechnology & Medical Research (NEC) United Kingdom
Fort Aggregator LP and The Prudential Assurance Company Limited 4basebio PLC

2024

Growth Equity & Expansion Capital Biotechnology & Medical Research (NEC) United Kingdom
N4 Partners NeuroClin

2024

Growth Equity & Expansion Capital Biotechnology & Medical Research (NEC) United Kingdom
Rockpool TalarMade

2024

Growth Equity & Expansion Capital Medical Equipment, Supplies & Distribution (NEC) United Kingdom

Marlin Equity Partners

invested in

Radar Healthcare

in 2024

in a Growth Equity & Expansion Capital deal

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert